Description

Vertex Pharmaceuticals: The Big Diversification Bet Beyond Cystic Fibrosis Taking Shape!

Vertex Pharmaceuticals reported first quarter 2026 total product revenue of $2.99 billion, marking an 8% year-over-year increase. Growth was driven primarily by continued performance in its cystic fibrosis (CF) franchise, which saw 6% global revenue growth, aided by U.S. and international uptake of ALYFTREK and TRIKAFTA, including recent label expansions that increased patient eligibility to approximately 95% of CF individuals. ALYFTREK exceeded $1 billion in cumulative revenue, and additional submissions for younger patient populations are underway. However, the company discontinued its VX-522 mRNA therapy program for patients producing no CFTR protein due to unresolved tolerability issues, limiting potential expansion in this segment. The company’s diversification efforts showed progress as products in newer disease areas—specifically CASGEVY for sickle cell and beta-thalassemia and JOURNAVX for moderate to severe acute pain—contributed about 25% of total product revenue growth.